Are There Clinical Differences in Limited Systemic Sclerosis according to Extension of Skin Involvement?

Table 1

Clinical and serological profiles of the 234 patients.

Subset of SSc	Limited ( = 178)		(sclero. versus acro.)	Diffuse ( = 56)	(limited versus diffuse)
	Sclerodactyly ( = 149)	Acrosclerosis ( = 29)
Females, (%)	142 (95,3)	25 (86,2)	0,06	49 (87,5)	0,13
Age at diagnosis, years, mean (SD)	59,8 (15,2)	54,9 (16,2)	0,14	53 (18,3)	0,038
Duration of Raynaud’s prior to diagnosis, years, mean (SD)	9,2 (3,4)	5,5 (1)	0,018	1,9 (0,8)	0,008
Anti-Scl-70, (%)	9 (6,4)	11 (39,3)	<0,001	18 (43,9)	<0,001
Anticentromere, (%)	116 (82,3)	5 (17,9)	<0,001	2 (4,8)	<0,001
Nucleolar ANA, (%)	8 (5,7)	1 (3,6)	0,54	9 (20,9)	0,001
Upper GI involvement, %	65,9	81,3	0,22	64,3	0,45
Interstitial lung disease, %	17,1	50	<0,001	65,3	<0,001
Pulmonary hypertension + interstitial lung disease, %	5,5	0	0,34	15,4	0,03
Isolated pulmonary hypertension, %	9,1	4,8	0,45	2,6	0,39
Cardiac ultrasound abnormalities (aside from PHT), %	5,7	4,5	0,65	10	0,26
Digital ulcers, %	26,9	34,5	0,44	32,1	0,86
Renal crisis,	0	0		1
Follow-up, patient/years-years (SD)	462 (3,1)	81,2 (3,1)		144,8 (3,6)
Being followed presently, (%)	88 (59,5)	15 (51,7)		26 (46,4)
Deaths during follow-up, at our institution,	11	2		4